VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.
Metrics to compare | VNRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVNRXPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −5.7x | −0.5x | |
PEG Ratio | 0.00 | −0.10 | 0.00 | |
Price/Book | 0.0x | 1.3x | 2.6x | |
Price / LTM Sales | 0.0x | 4.1x | 3.0x | |
Upside (Analyst Target) | 0.0% | 173.9% | 54.1% | |
Fair Value Upside | Unlock | 2.5% | 9.4% | Unlock |